论文部分内容阅读
目的:观察益脾清肺经验方联合化疗治疗中晚期非小细胞肺癌的临床效果。方法:将94例中晚期非小细胞肺癌肺脾气虚兼痰热证患者随机分为对照组和观察组各47例。2组均给予TP方案化疗,观察组则加用益脾清肺经验方内服治疗,3周为1疗程,连续治疗2疗程。比较2组的近期疗效,检测治疗前后糖类抗原(CA125)、癌胚抗原(CEA)、神经元特异性烯醇化酶(NSE)等肿瘤标志物水平的变化,用癌症治疗功能性量表(FACT-L)评估2组患者生存质量的改善情况。结果:观察组有效率为63.8%,对照组有效率为34.0%,2组比较,差异有统计学意义(P<0.01)。治疗后,2组CA125、CEA、NSE水平均低于治疗前(P<0.05),观察组各指标水平均低于对照组(P<0.05);观察组与生活质量相关的生理、情感、活动功能、社会/家庭状况的评分均高于对照组(P<0.05)。结论:益脾清肺经验方联合化疗治疗中晚期非小细胞肺癌近期疗效确切,能显著提高患者的生活质量,其机制可能与可调控血清肿瘤标志物的水平有一定相关性。
Objective: To observe the clinical efficacy of Yipi Qingfei Decoction combined with chemotherapy in the treatment of advanced non-small cell lung cancer. Methods: Ninety-four patients with non-small cell lung cancer of lung, spleen and qi and phlegm were randomly divided into control group and observation group, with 47 cases each. Two groups were given TP chemotherapy, the observation group was treated with Yipi Qingfei oral treatment, 3 weeks for a course of treatment, continuous treatment 2 courses. The curative effect of two groups were compared before and after treatment to detect the changes of tumor markers such as carbohydrate antigen (CA125), carcinoembryonic antigen (CEA) and neuron specific enolase (NSE) FACT-L) to assess the improvement in quality of life in both groups. Results: The effective rate was 63.8% in the observation group and 34.0% in the control group. There was significant difference between the two groups (P <0.01). After treatment, the levels of CA125, CEA and NSE in the two groups were lower than those before treatment (P <0.05), and the levels of each index in the observation group were lower than those in the control group (P <0.05). The physical, emotional and activity related quality of life Function, social / family status were higher than the control group (P <0.05). Conclusion: The short-term curative effect of Yipi Qingfei prescription combined with chemotherapy on advanced non-small cell lung cancer can significantly improve the quality of life of patients, which may be related to the level of serum tumor markers.